AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $494.83 ($489.61–$499.07, $4.70M total) across 10 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 23, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The sale reduces insider ownership and could be interpreted as a bearish signal, but the 10b5‑1 plan suggests it was scheduled, limiting predictive power.

02

Market read

First‑report insider sale provides fresh data for traders monitoring executive activity.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 7/10Timing: post‑market filing on 2026‑09‑22

Background

SEC Form 4 filing discloses insider transactions required by regulation.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine A. Rothblatt sold 9,500 shares for $4.7M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Potential short‑term pressure on UTHR as the market digests the large insider sale.

Evidence & confidence

A $4.7M sale by the top executive signals possible concerns about valuation; however, the sale is pre‑arranged under a 10b5‑1 plan, limiting immediate interpretive weight.

Market effects

Sector

May raise caution for biotech/therapeutics sector investors.

Regional

Limited to U.S. markets where UTHR trades.

Global

Minimal global effect beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale is pre‑arranged and may not reflect insider sentiment; price could remain stable.

Key entities

  • Company
    United Therapeutics Corp

    NASDAQ‑listed biotech firm (ticker UTHR).

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min